Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Corren

Showing results (81-90 of 141) with videos related to

Pageof 15
Sort By:
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 26, 2004
Addition of ibuprofen to pseudoephedrine and chlorpheniramine in the treatment of seasonal allergic rhinitisEli O Meltzer, Gary D Berman, Jonathan Corren, et al.
American Journal of Respiratory and Critical Care Medicine|January 9, 2010
A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthmaJonathan Corren, William Busse, Eli O Meltzer, et al.
Allergy|December 26, 2023
Tezepelumab in patients with allergic and eosinophilic asthmaMarco Caminati, Roland Buhl, Jonathan Corren, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|March 6, 2023
Dupilumab long-term efficacy in patients with non-OCS-dependent asthma with and without evidence of allergic asthmaLawrence D Sher, Jonathan Corren, Ian D Pavord, et al.
The Journal of Allergy and Clinical Immunology|February 16, 2025
Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION studyJulie McLaren, Yun Chon, Kevin S Gorski, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 28, 2023
Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthmaAnju T Peters, Hironori Sagara, Jonathan Corren, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 1, 2023
Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: The NAVIGATOR studyAndrew Menzies-Gow, Arnaud Bourdin, Geoffrey Chupp, et al.
The European Respiratory Journal|March 30, 2023
Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyondJonathan Corren, Christopher E Brightling, Louis-Philippe Boulet, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 26, 2004
Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposureTamara T Perry, Jonathan Corren, George Philip, et al.
International Forum of Allergy & Rhinology|December 31, 2021
Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS-24 and SINUS-52 trialsClaus Bachert, Jonathan Corren, Stella E Lee, et al.
Pageof 15

Showing results (81-90 of 141) with videos related to

Sort By:
Pageof 15
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 26, 2004
Addition of ibuprofen to pseudoephedrine and chlorpheniramine in the treatment of seasonal allergic rhinitisEli O Meltzer, Gary D Berman, Jonathan Corren, et al.
American Journal of Respiratory and Critical Care Medicine|January 9, 2010
A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthmaJonathan Corren, William Busse, Eli O Meltzer, et al.
Allergy|December 26, 2023
Tezepelumab in patients with allergic and eosinophilic asthmaMarco Caminati, Roland Buhl, Jonathan Corren, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|March 6, 2023
Dupilumab long-term efficacy in patients with non-OCS-dependent asthma with and without evidence of allergic asthmaLawrence D Sher, Jonathan Corren, Ian D Pavord, et al.
The Journal of Allergy and Clinical Immunology|February 16, 2025
Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION studyJulie McLaren, Yun Chon, Kevin S Gorski, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 28, 2023
Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthmaAnju T Peters, Hironori Sagara, Jonathan Corren, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 1, 2023
Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: The NAVIGATOR studyAndrew Menzies-Gow, Arnaud Bourdin, Geoffrey Chupp, et al.
The European Respiratory Journal|March 30, 2023
Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyondJonathan Corren, Christopher E Brightling, Louis-Philippe Boulet, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 26, 2004
Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposureTamara T Perry, Jonathan Corren, George Philip, et al.
International Forum of Allergy & Rhinology|December 31, 2021
Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS-24 and SINUS-52 trialsClaus Bachert, Jonathan Corren, Stella E Lee, et al.
Pageof 15